Quantcast

Latest Tapentadol Stories

2010-10-17 13:00:00

SAN CARLOS, Calif., Oct. 17 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine. These data were presented during the poster session entitled "Chronic and Cancer Pain" held today at the American Society of Anesthesiologists (ASA 2010) Annual Meeting on October 17, 2010 in...

2010-10-15 06:30:00

SAN CARLOS, Calif., Oct.15 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies. The data are being featured in an oral abstract session and poster presentation today at the 5th Annual...

2010-10-07 14:17:00

NASHVILLE, Tenn., Oct. 7 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of data affirming the safety and efficacy of Caldolor® (ibuprofen) Injection in treating fever in critically ill and non-critically ill adults. Published in the peer-reviewed journal Critical Care, the study showed that IV ibuprofen was significantly more effective at reducing fever in hospitalized patients than placebo. "These findings demonstrate...

2010-10-04 07:01:00

RARITAN, N.J., Oct. 4 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for tapentadol extended release tablets. The application, filed by J&JPRD in late 2009 [see press release at http://www.jnj.com/connect/news/product/20091201_200000], seeks approval to market tapentadol extended...

2010-09-27 07:30:00

RARITAN, N.J., Sept. 27 /PRNewswire/ -- Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic low back pain have been published online by Expert Opinion on Pharmacotherapy. In addition, this study compared oxycodone controlled-release (CR) to placebo as an active control. Tapentadol ER vs. Placebo The study demonstrated that a significantly higher percentage of...

2010-09-23 12:28:00

NASHVILLE, Tenn., Sept. 23 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that Caldolor® (ibuprofen) Injection is gaining momentum and being approved for use in a growing number of medical facilities across the country. Several key U.S. hospitals, including Orlando Regional Medical Center, St. Elizabeth Healthcare in the Greater Cincinnati region and the Joseph M. Still Burn Centers, have added the product to their formularies for patient...

2010-09-22 07:59:00

MILAN, September 22, 2010 /PRNewswire/ -- After having handled the worldwide launch of tapentadol, the innovative drug for the severe acute pain, Alberto Grua has been appointed Grunenthal Europe and Australia Executive Vice President. Beyond the responsibility of the Grunenthal subsidiaries Grunin both continents, Grua will be also a member of the Group Operating Committee of Grunenthal Corporation. (Photo: http://www.newscom.com/cgi-bin/prnh/20100922/409552 ) Previously, Grua...

2010-09-09 12:07:00

STAMFORD, Conn., Sept. 9 /PRNewswire/ -- Purdue Pharma L.P. will present data from the clinical program for Butrans(TM) (buprenorphine) Transdermal System CIII in a series of posters at PAINWeek® 2010, September 8-10 in Las Vegas. Butrans recently received marketing approval from the U.S. Food and Drug Administration and is expected to be commercially available in the U. S. during the first quarter of 2011. The featured studies evaluated the safety and efficacy of...

2010-09-02 07:00:00

MONTREAL, Sept. 2 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, announced today the final data set from its Phase 3 study of Ketotransdel® (TDLP-110) at the 13th World Congress on Pain in Montreal, Canada. TDLP-110, the Company's lead pain product candidate, utilizes its transdermal delivery...

2010-08-31 08:30:00

SYDNEY and BEDMINSTER, N.J., Aug. 31 /PRNewswire/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today it will sponsor a symposium at the 13th World Congress of Pain on 31 August, 2010 at Palais des congres de Montreal. The symposium, titled "Dual Opioid Therapy: Changing the Paradigm" will focus on preclinical and clinical data for MoxDuo®IR, an immediate-release Dual Opioid product for moderate to severe acute pain. Featured speakers who will highlight Dual...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related